Physician profile
Eric R Anderson
NPI 1952763328
$102,742.50
in general payments reported to CMS, 2019-2025
9 companies · $74K in 2025
The $74K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2022: $284 · 2023: $1,423 · 2024: $27K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Consulting Fee: $41K · Travel and Lodging: $11K · Food and Beverage: $5,276 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,150.00 |
| Consulting Fee | $40,508.75 |
| Travel and Lodging | $11,170.18 |
| Food and Beverage | $5,276.01 |
| Education | $123.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $55,915.74 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $17,036.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $13,953.09 | 2019-2025 | Benlysta |
| Abbvie INC. | $12,231.84 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $2,379.99 | 2024-2025 | Tremfya |
| Amgen INC. | $852.45 | 2023-2025 | Tavneos, Otezla, Evenity |
| Lilly USA, LLC | $205.04 | 2024 | Taltz |
| Genzyme Corporation | $95.81 | 2024 | |
| Janssen Scientific Affairs, LLC | $72.17 | 2024-2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.